Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $1.6 million with four lenders (including Scott M. Pittman and Paul Anthony Jacobs) at annual rate of 10% maturing December 31, 2028.
“On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million with (a) $1.0 million funded on the initial closing date (the “Initial Funding”) and (b) $600 thousand to be funded, if requested in advance by the Company and subject to closing conditions, on September 30, 2026 (the “Second Funding”).”
Material Agreements
Nuo Therapeutics, Inc. entered into Loan and Security Agreement with four lenders (collectively, the "Lenders") valued at up to $1.6 million (effective 2026-01-21).
“On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.